医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical

2021年03月03日 AM10:00
このエントリーをはてなブックマークに追加


 

DUBLIN, Ireland

ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a license agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka). The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

Eric Rhodes, CEO of ERS Genomics, said:We are extremely pleased to be able to provide Otsuka with access to the CRISPR/Cas9 license. We hope this brings significant value to Otsuka as it applies the technology to its internal programs.”

Financial details of the agreement are not disclosed.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan.

ENDS

For high resolution images please contact Zyme Communications

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302006126/en/

CONTACT

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 502 947

Email: katie.odgaard@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • GC Pharma Lights Up to Celebrate ‘World Hemophilia Day’
  • ノクソファームが敗血症性ショック治療の効用でビヨンダの特許を出願
  • 东阳光药选择ABEC大型发酵罐以提高生物制药生产能力
  • Aural Analytics, Inc. and Healint, Pte. Ltd. Partner on Integration of Speech Analytics into Healint’s Suite of Clinical Trials and Widely Used Consumer Applications
  • Anji Pharma Adds Clinical Sites to Accelerate Clinical Development of Pradigastat for the Treatment of Functional Constipation